Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
26 authors.
Ruby Pandher *Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.
Chengyuan Xue *Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.ORCID 0009-0000-8057-1134
Laura D GambleChildren's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.ORCID 0000-0001-8496-9705
Giorgio MilazzoDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.ORCID 0000-0002-1930-4763
Simone Di GiacomoDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.ORCID 0000-0003-4409-2421
Jayne MurrayChildren's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.
Leanna CheungChildren's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.ORCID 0009-0008-7447-2728
Francesca FerrucciDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.
Marta PalomboDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.
Stefania PurgatoDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.
Catherine A BurkhartBuffalo BioLabs, Limited Liability Company, Buffalo, NY 14203.ORCID 0009-0000-1906-6809
Natalia FedtsovaDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203.
Thomas J TelferSchool of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-5838-2537
Rachel CoddSchool of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-2703-883X
Glenn M MarshallChildren's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.ORCID 0000-0002-2503-0762
David A ScottSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.ORCID 0000-0002-8668-2449
Andrei L OstermanSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.ORCID 0000-0002-3810-9824
Andrei V GudkovDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203.ORCID 0000-0003-2548-0154
Giovanni Perini *Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.ORCID 0000-0002-0150-8477
Michelle Haber *Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.ORCID 0000-0003-2036-8817
Murray D Norris *Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.ORCID 0000-0002-0632-4589
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
N-myc Targeted Therapeutics for Childhood NeuroblastomaR44CA110885 · NCI · CLEVELAND BIOLABS, INC. · PI BURKHART, CATHERINE A · 2006 to 2007
$750k
N-myc Targeted Therapeutics for Childhood NeuroblastomaR43CA110885 · NCI · CLEVELAND BIOLABS, INC. · PI BURKHART, CATHERINE A · 2004 to 2004
$100k
Cancer Institute NSW (Cancer Institute New South Wales) 10/TPG/1-03Cancer Institute NSW (Cancer Institute New South Wales) 14/TPG/1-13Federal Government | DHAC | National Health and Medical Research Council (NHMRC) APP1016699Federal Government | DHAC | National Health and Medical Research Council (NHMRC) APP1132608Fondazione AIRC per la ricerca sul cancro ETS (AIRC) IG15182Fondazione AIRC per la ricerca sul cancro ETS (AIRC) IG24241NCI NIH HHS P30 CA030199NCI NIH HHS R43 CA110885NCI NIH HHS R44 CA110885Neuroblastoma Australia research grantTour de Cure (TDC) Research grant
6 · The paper itself
Abstract
Despite Myc oncoproteins being major causal factors in human cancer, they remain "undruggable." The
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response. · full record | OpenQuestion